Our study sheds light on how mutations affecting the cohesin complex alter the biology of mutant MDS and leukemia cells in a manner that creates a specific therapeutic vulnerability to PARP inhibitors. This evidence concerns the gene PARP1 and myelodysplastic syndrome.